



PUBLICATIONS

- Goldfarb J, Baley J, Vanderbrug Medendorp S, Seto D, Garcia H, Toy P, Watson B, Gooch M, **Krause DS**. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. *Pediatr Infect Dis J*, 1994;13:18-22.
- Bernstein HH, Rothstein EP, and Pennridge Pediatric Associates, Resisinger KS, Blatter MM, Arbeter AM, Fontana ME, Jacobs JM, Long SS, Rathfon H, Crayne O, **Krause DS**. Comparison of a three-component acellular pertussis vaccine with a whole cell pertussis vaccine in 15 through 20 month old infants. *Peds*, 1994;93:656-659.
- Schiff GM, Sherwood JR, Zeldis JB, **Krause DS**. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. *J Adol Health*, 1995;16:12-17.
- DeFraitres RF, Feighner BH, Binn LN, Kanjarpane DD, Delem AD, MacArthy PO, Krauss MR, **Krause DS**, Moonsammy GI, and Hoke CH. Immunization of US soldiers with a two-dose primary series of inactivated hepatitis A vaccine: early immune response, persistence of antibody, and response to a third dose at 1 year. *J Infect Dis*, 1995;171(Suppl 1) S61-69.
- Balcarek KB, Bagley MR, Pass RF, Schiff ER, **Krause DS**. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. *J Infect Dis*, 1995;171(Suppl 1) S70-72.
- McMahon BJ, Williams J, Bulkow L, Snowball M, Wainwright R, Kenneoy M, **Krause DS**. Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and non-native adults. *J Infect Dis*, 1995;171:676-79.
- Schoen RT, Meurice F, Brunet CM, Cretella S, **Krause DS**, Craft JE, Fikrig F. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. *J Infect Dis*, 1995; 172: 1324-29.
- Rustgi VK, Schleupner CJ, **Krause DS**. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1 and 6 months in healthy adults. *Vaccine* 1995; 13:1665-8.
- Bernstein HH, Rothstein EP, **Krause DS**, et al. Reactogenicity and immunogenicity of a three- component acellular pertussis vaccine administered as the primary series to 2-, 4- and 6-month- old infants in the United States. *Vaccine* 1995; 13:1631-5.
- Goldfarb J, Vanderburg M, Garcia H, Nagamouri K, Rathfon H, **Krause DS**. Comparison study of the immunogenicity and safety of 5 and 10 mg dosages of a recombinant hepatitis B vaccine in healthy infants. *Pediatr Infect Dis J*, 1996; 15:764-7.
- Meurice F, Parenti D, Fu D, **Krause DS**. Specific issues in the design and implementation of an efficacy trial for a Lyme disease vaccine. *Clin Infect Dis*, 1997; 25 (Suppl 1):S71-5.
- Troisi CL, Hollinger FB, **Krause DS**, Pickering LK. Immunization of seronegative infants with hepatitis A vaccine: a comparative study of two dosing schedules. *Vaccine* 1997;15:1613-7.
- Keefe EB, Iwarson S, McMahon BJ, Lindsay K, Koff RS, Manns M, Baumgarden R, Wiese M, Forneau M, Safary A, Clemens R, **Krause DS**. Safety and Immunogenicity of hepatitis A vaccine in patients with chronic liver disease. *Hepatology* 1998; 27: 881-5.
- Steere AC, Sikand VJ, Meurice F, Parenti DL, Fikrig E, Schoen RT, Nowakowski J, Schmid CH, Laukamp S, Buscarino C, **Krause DS**. Vaccination against Lyme disease with recombinant *Borrelia burgdorferi* outer-surface lipoprotein A with adjuvant. *N Engl J. Med* 1998; 339: 209-15.
- Letson W, Shapiro CN, Kuhlen D, Gardea C, Welty T, **Krause D**, Lambert S, Margolis H. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. *J Peds* 2004; 144: 327- 332.

PUBLICATIONS - CONTINUED

Dowell JA, Knebel W, Ludden T, Stogniew M, **Krause D**, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. *J Clin Pharm* 2004; 44: 590-598.

Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T. A Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. *Antimicrob Agents Chemother* 2004; 48: 2021-2024.

Krause DS, Simjee AE, Van Rensberg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel TJ. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. *Clin Infect Dis* 2004; 39: 770-5.

Dowell JA, Stogniew M, **Krause D**, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. *J Clin Pharmacol* 2005; 45: 227-233.

Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievans D, Fredrick M, **Krause D**, et al. Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid in the Treatment of Complicated Skin and Skin Structure Infections. *Clin Infect Dis* 2005; 41:1407-15.

Dowell JA, Seltzer S, Fayocavitz S, Buckwalter M, Stogniew M, **Krause DS**. The pharmacokinetics, safety, and tolerability of intravenous dalbavancin in subjects with moderate and severe hepatic impairment. Submitted *J Clin Pharmacol*.

Dowell JA, Stogniew M, **Krause D**, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. *J Clin Pharmacol* 2007; 47: 305-14.

Dowell JA, Stogniew M, **Krause DS**, Damle, B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. *Journal of Clinical Pharmacology*, 2007; 47:461-470

Reboli A, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, **Krause DS**, Walsh TJ. A double-blind, randomized, multi-center, non-inferiority study of the safety and efficacy of anidulafungin versus fluconazole in the treatment of patients with candidemia and other forms of invasive candidiasis. *New Eng J Med* 2007: 356; 2472-82.

Binkley N, Bolognese M, Sidorowicz-bialynicka A, **Krause DS** et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. *J Bone Miner Res*. 2012;27(8):1821-9.

Perlis RP, Dowd D, Fava M, Lencz T, **Krause DS**. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. *Depress Anxiety*. 2018;1-7

King CD, Yip AG, Cao YA, Rodriguez-Villa, F, **Krause DS**. Dowd, D, Ressler K. Open-label pilot study of psychiatric pharmacogenetic testing in an adult psychiatric inpatient population. *Pers Med Psych* 2020. Published online 02 Sept <https://doi.org/10.1016/j.pmip.2020.100060>

Krause DS, Dowd D. Use of a Consultation Service Following Pharmacogenetic Testing in Psychiatry. *Pharmacogenomics*. 2022 Apr;23(5):327-333

Dowd D, Williams G, Cunningham E, Clarke S, **Krause D**, Saklad S. Predicting potential gene- drug interactions in a population of individuals using a community pharmacy *CNS Spectrums*, Volume 27, Issue 2, April 2022, pp. 236 – 237.

Dowd D, **Krause DS**. Moving to real world applications of pharmacogenetic testing. *J Precision Med*, 2022, 8(4).

Cecil L, Dowd D, Patel S, **Krause DS**. The utility of pharmacogenetics in a patient with terminal illness: a case report. *Clin Case Reports* 2023, 13:05.

ABSTRACTS

Kanjarpane DD, DeFraités RF, Hoke CH, Sanchez JL, Malis DJ, Gelnett JM, Fleming JL, Krauss MR, Egan JE, Sjogren MH, Moonsammy GI, **Krause DS**: Safety of hepatitis A vaccine (HM 175, inactivated--SmithKline Beecham) in U.S. soldiers: Comparison of immunization schedules. American Society of Tropical Medicine and Hygiene, 1991.

Safary A, **Krause DS**, D'Hondt E, and Andre F: Safety and immunogenicity of hepatitis A vaccine in young healthy adults. Abstract 1101. The 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991.

Masar J, Safary A, **Krause D**, Boscia J, Moonsammy G, André F: Safety and immunogenicity of an inactivated hepatitis A virus vaccine in children. American Pediatric Society, New Orleans, 1991.

Tong M, Co R, Bellak C, **Krause D**: Evaluation of the safety and immunogenicity of an inactivated hepatitis A virus (HAV) vaccine in healthy adults. Abstract 1381. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992.

Sherwood J, Young E, Bellak C, **Krause D**, Schiff G: Evaluation of the safety and immunogenicity of three dosing schedules of an inactivated hepatitis A virus (HAV) vaccine in healthy adults. Abstract 1382. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992.

Davidson M, Krugman S, Crayne O, **Krause D**: Evaluation of the safety and immunogenicity of an inactivated hepatitis A (HM 175) vaccine in healthy adult volunteers. Abstract 1383. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992.

Schiff G, Sherwood J, Young E, Rathfon H, **Krause D**: Safety and immunogenicity of an inactivated hepatitis A virus (HAV) vaccine in healthy adolescents. Abstract 1385. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992.

Sack M, Rustgi V, Levison M, **Krause D**: Safety and immunogenicity of immune globulin versus two dosing schedules of an inactivated hepatitis A (HA) vaccine in healthy adult travelers.

Abstract 256. Third Conference on International Travel Medicine, 1993.

DeFraités R, Feighner B, Hoke C, Binnal, MacArthy J, Sanchez D, Kanjarpane G, Moonsammy G, **Krause D**, D'Hondt E: Rapid immunization with hepatitis A vaccine in U.S. soldiers. Abstract

028. International Symposium on Viral Hepatitis and Liver Disease (Eighth Triennial Congress) 1993.

McMahon B, Williams J, Bulkow L, Snowball M, Wainwright R, **Krause D**, Boscia J, Moonsammy G: Response to Hepatitis A vaccine in Alaska native children and native and non- native adults. Abstract 036. International Symposium on Viral Hepatitis and Liver Disease (Eighth Triennial Congress) 1993.

Shapiro C, Letson G, Kuehn D, Welty T, **Krause D**, Lambert S, Margolis H: Immunogenicity and reactogenicity of inactivated hepatitis A vaccine in infants. Abstract 038. International Symposium on Viral Hepatitis and Liver Disease (Eighth Triennial Congress) 1993.

Blumer J, Goldfarb J, Lemon E, Rathfon H, **Krause D**: A comparative study of the immunogenicity and safety of two doses of Engerix-B in healthy neonates. The 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993.

Pichichero M, Green J, Francis A, Marsocci S, Lyne A, Litterer T and **Krause D**. Safety and immunogenicity of a three component acellular pertussis vaccine (DTaP) compared to whole cell DTP (DTwP) vaccine in infants. Abstract 183. The 33rd Interscience Conference on Agents and Chemotherapy, 1993.

Balacarek KB, Bagley MR, Pass RF, **Krause D**. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. Clin Research, 1993;41:(no.4):10.

ABSTRACTS - CONTINUED

Rustgi V, Schlepner C, Bellak C, **Krause D**. Immunogenicity of Engerix-B given at 0,1,2,12 months and Recombivax HB given at 0,1,6 months. *Gastro*, 1994;106(4 Part 2):A972.

Goldfarb J, Nagamori K, Buscarino C, **Krause D**. A comparative study of the immunogenicity and safety of two doses of Engerix-B in healthy children. Abstract H127. The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994.

Blatter MM, Reisinger KS, Kammerer LC, Kobasa WD, **Krause D**. Comparative safety and immunogenicity of a new formulation of hepatitis B vaccine and of Engerix-B administered at 2,4 and 6 months of age. Abstract H129. The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994.

Goldfarb J, Garcia H, Nagamori K, Rathfon H, **Krause D**. A comparative study of the immunogenicity and safety of two doses of Engerix-B in healthy infants. Abstract H131. The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994.

Meurice F, Schoen R, **Krause D**, Fikrig E. Administration of an outer surfact protein A (OspA) Lyme disease (LD) vaccine in subjects with previous LD. Abstract G30. The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995.

Telford S, Krause P, Meurice F, **Krause D**, Lepore T, Brassard D, Hoxsie R, Christiansen D, Speilman A. Safety and Immunogenicity of a candidate Lyme disease vaccine in residents of epidemic New England sites. Abstract G31. Proceedings of the 35th Interscience Conference on Antimicrobial Agents in Chemotherapy, 1995.

Shapiro C, Letson G, Kuehn D, Welty T, **Krause D**, Lambert S, Margolis H. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. Abstract. The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995.

Greenberg DP, Marcy SM, Wong UK, Vadheim CM, Partridge S, **Krause D**, Howe BJ, Margolis HS, Ward JI. Evaluation of recombinant hepatitis B vaccine given to infants at 2, 4, and 6 months of age in the U.S. Abstract C306. IX Triennial International Symposium on Viral Hepatitis and Liver Disease, 1996.

Meurice F, Buscarino CJ, Verity DE, Gillet M, **Krause DS**. A field trial to test the clinical efficacy of a Lyme disease candidate vaccine. Abstract H1424. VII International Congress on Lyme Borreliosis, 1996.

Krause DS. Vaccine R&D priorities for travel medicine. Abstract S13. Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996.

Steere AC, Sikand VK, Schoen RT, Parenti DL, **Krause DS**. Successful vaccination for Lyme disease (LD) using a recombinant, adjuvanted *Borrelia burgdorferi* outer surface protein lipoprotein A. Abstract 761. Infectious Disease Society of America 35th Annual Meeting, 1997.

Krause DS. Introduction to Surrogate Markers. Abstract S5. First Annual Conference on Vaccine Research, 1998.

Dowell J, Stogniew M, **Krause D**: Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Abstract p1222. 13th European Congress of Clinical Microbiology and Infectious Disease, 2003.

Krause D, Goldstein B, Wible M, Kilfoil G, Henkel T: A Phase 2 dose-ranging study of the safety and efficacy of anidulafungin in invasive candidiasis. Abstract O403. 13th European Congress of Clinical Microbiology and Infectious Disease, 2003.

Dowell J, Seltzer E, Stogniew M, Dorr MB, Fayocavitz S, **Krause D**: Dalbavancin dosage adjustments not required for patients with mild renal impairment. Abstract p1224. 13th European Congress of Clinical Microbiology and Infectious Disease, 2003.

ABSTRACTS - CONTINUED

Dowell J, Pu F, Lee J, Stogniew M, **Krause D**, Henkel T: A clinical mass balance study of anidulafungin (ANID) showing complete fecal elimination. Abstract: A-1576. 43rd ICAAC Abstracts, American Society for Microbiology, September, 2003, page 32.

Dowell J, Knebel W, Ludden T, Stogniew M, **Krause D**, Henkel T: A population pharmacokinetic analysis of anidulafungin. Abstract: A-1575. 43rd ICAAC Abstracts, American Society for Microbiology, September, 2003, page 31.

Dowell J, Stogniew M, **Krause D**, Henkel T: Anidulafungin (ANID) pharmacokinetic (PK)/pharmacodynamic (PD) correlation: treatment of esophageal candidiasis (EC). Abstract: A-1578. 43rd ICAAC Abstracts, American Society for Microbiology, September, 2003, page 32.

Krause D, Henkel T, Goldstein B, Walsh T: Anidulafungin (ANID) vs. Fluconazole (FLU) in esophageal candidiasis (EC): a phase 3, randomized, double-blind, multicenter trial. Abstract: M-1760. 43rd ICAAC Abstracts, American Society for Microbiology, September, 2003, page 477.

Dowell J, Seltzer E, Stogniew M, Dorr MB, Fayocavitz S, **Krause D**, Henkel T: Dalbavancin (DAL) pharmacokinetics (PK) in subjects with mild or moderate hepatic impairment (HI).

Abstract: A-19. 43rd ICAAC Abstracts, American Society for Microbiology, September, 2003, page 4.

Schranz J, **Krause D**, Goldstein B, Henkel T: Efficacy of anidulafungin (ANID) for the treatment of candidemia. Abstract: M-971. 43rd ICAAC Abstracts, American Society of Microbiology, September, 2003, page 448.

Krause D, Birmingham W, Schranz J: Safety results from a Phase 3, randomized, double-blind, double-dummy study of anidulafungin vs fluconazole in patients with esophageal candidiasis.

Abstract: 136. The 41st Meeting of the Infectious Disease Society of America, 2003.

Herbrecht R, Graham D, Schuster M, Henkel T, **Krause D**, Schranz J, Garbino J, Caillot D, Reinhardt J, Maertens J. Safety and Tolerability of Combination Anidulafungin (ANID) and Liposomal Amphotericin B (LAmB) for the Treatment of Invasive Aspergillosis (IA). 2004 Tandem BMT Meetings, Orlando. 15 February 2004, Abstract # 150226.

Dowell J, Schranz J, Stogniew M. **Krause D**, Henkel T. Assessment of the pharmacokinetics (PK) of anidulafungin (anid) in patients with invasive aspergillosis receiving concomitant liposomal amphotericin B (LAmB). Focus on Fungals. New Orleans LA, 2004.

Herbrecht R, Graham D, Schuster M, Henkel T, **Krause D**, Schranz J, Garbino J. Safety and tolerability of combination anidulafungin and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis. Focus on Fungals. New Orleans LA, 2004.

Krause D, Schranz J, Birmingham W. Lack of hepatic effect of anidulafungin (ANID). 14th European Congress of Clinical Microbiology and Infectious Disease, 2004.

Vazquez JA, Zervos MJ, Reinhardt J, **Krause DS**, Schranz J, Reboli A. Safety of IV anidulafungin in invasive candidiasis. Abstract. The 42nd Meeting of the Infectious Disease Society of America, 2004.

Dowell JA, Schranz J, Buckwalter M, **Krause D**. Safety and Pharmacokinetics of Co- Administered Anidulafungin and Tacrolimus. Abstract A-1190. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2005

Reboli A, Rotstein C, Pappas P, Schranz J, **Krause D**, Walsh TJ. Anidulafungin vs. Fluconazole for Treatment of Candidemia and Invasive Candidiasis (C/IC). Abstract 1451. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2005

ABSTRACTS - CONTINUED

Seltzer E, Goldberg L, **Krause D**. The safety of dalbavancin in a clinical development program. Abstract L-1576. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2005.

Morley P, Bishop J, Anderson R, Barclay CL, **Krause D**, Morelli G, Newhouse M, Sadrzadeh N, Eldon M. Pulmonary delivery of the parathyroid hormone analogue Ostabolin-C stimulates markers of bone formation in postmenopausal women. J Bone Miner Res 2007; 22: Suppl 1 Abs M421.

MacDonald B, **Krause D**. The effect of bodyweight on clinical Response to ZT-031: development of a simple, improved dosing regimen for PTH analogues. World Congress on Osteoporosis, Bangkok, December 6 2008.

MacDonald B, Vittinghoff E, Cummings, S, Bauer DC, **Krause D**. An active-controlled non-inferiority study to compare the effect of ZT-031 with alendronate on the incidence of new vertebral fracture: The PACE (cyclic PTH and alendronate comparative efficacy study).

Abstract M347. J Bone Min Res, 2008: 23; s360.

Krause D, P. Eddy P, Merutka G, MacDonald B. Intranasal (IN), Pharmacokinetic (PK) and Bioavailability of ZT-034 a Parathyroid Hormone (PTH) Analog. J Bone Miner Res 24 (Suppl 1). Available at:

<http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=82fc4983-2e7c-43d4-8528-cb051daf6d96>

Eddy P, **Krause D**, Merutka G, MacDonald B. Intranasal (IN) Pharmacokinetics (PK) and Bioavailability of ZT-031, a Novel Parathyroid Hormone (PTH) Analog. J Bone Miner Res 24 (Suppl 1). Available at:

<http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=d313773d-19b6-421e-aaf3-1e1708b09a77>

Krause D, Buben C, Gilligan J. A phase 1 study to evaluate the effect of food and gastric acid suppression on pharmacokinetics and pharmacodynamics of a novel oral calcitonin. Ninth International Symposium on Osteoporosis. Las Vegas, Nevada. Accepted.

Binkley N, Bolognese M, Sidorowicz-bialynicka A, **Krause DS**, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012;27(8):1821-9.

Boland JR, Duffy B, Myer NM, **Krause D**. Effectiveness of Pharmacogenomic testing in Individuals with SLC6A4 and/or MTHFR Polymorphisms and Major Depressive Disorder and/or Generalized Anxiety Disorder. Presented at 2017 Neuroscience Education Institute Congress, November 8-12, Colorado Springs CO.

Dowd D, **Krause DS**. Use of a consultation service following pharmacogenomics testing in psychiatry. CNS Spectr 2021 Apr; 26 (2); 179-80.